Form 4: Akebia Therapeutics Director Cynthia Smith Receives Equity Compensation Grant

Akebia Therapeutics, Inc. Director Cynthia Smith was granted 35,700 restricted stock units and options to purchase 53,600 shares of common stock as part of her compensation.

Summary

• Cynthia Smith, a Director at Akebia Therapeutics, Inc. (AKBA), received a grant of equity compensation on June 10, 2025.
• The grant included 35,700 restricted stock units (RSUs) at a price of $0.00 per unit, increasing her direct beneficial ownership to 160,933 common shares.
• Additionally, she was granted stock options to purchase 53,600 shares of common stock with an exercise price of $3.92 per share.
• Both the RSUs and stock options were granted under the Issuer's 2023 Stock Incentive Plan and the Fourth Amended and Restated Non-Employee Director Compensation Program.
• The RSUs and stock options are set to vest in full (100%) on the first anniversary of the grant date, or earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the grant date, contingent upon her continued service to the Issuer.
• The stock options have an expiration date of June 10, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard, positive event of director compensation through equity grants, aligning interests and incentivizing continued service. There are no negative implications or risks disclosed.

Positives

• The equity grants align the interests of Director Cynthia Smith with those of the shareholders, as her compensation is tied to the company's stock performance.
• The grants are part of a pre-established compensation program, indicating a structured approach to director remuneration and retention.

Future Outlook

The restricted stock units and stock options are subject to future vesting, which will occur in full on the first anniversary of the grant date (June 10, 2026) or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the grant date, provided the reporting person continues her service to the Issuer.

Industry Context

This filing is a routine disclosure of director compensation in the biotechnology sector. Equity grants are a common practice in the industry to attract and retain talent, aligning management and director interests with long-term shareholder value, particularly in companies like Akebia Therapeutics that rely on long-term drug development cycles.

Comparison to Industry Standards

• The use of restricted stock units and stock options for non-employee director compensation is a standard practice across the biotechnology and pharmaceutical industries, comparable to compensation structures seen at companies like Sarepta Therapeutics, Vertex Pharmaceuticals, or Biogen, which also utilize equity-based incentives to align director interests with company performance and shareholder value.
• The vesting schedule, typically tied to continued service over one year or until the next annual meeting, is also consistent with common corporate governance practices for non-executive directors in publicly traded companies.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units and stock options to Cynthia Smith, a Director of Akebia Therapeutics, constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with shareholder value, potentially leading to more aligned decision-making aimed at increasing stock price.
• Employees: While not directly impacting employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The restricted stock units and stock options will vest on June 10, 2026, or earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the grant date, subject to continued service.

Key Dates

Keywords

Akebia Therapeutics, AKBA, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Compensation, Director Compensation, Biotechnology, Pharmaceuticals